These four large-cap stocks recently announced buyback programs that are moderate to massive in size when compared to their market capitalizations. I’ll break down these new programs, as well as other ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Market Perform to Outperform. Analyst Price Forecast Suggests 42.56% ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price lowered by equities researchers at Bernstein Bank from $1,070.00 to $1,000.00 in a research note issued to investors on ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price decreased by equities research analysts at Leerink Partners from $980.00 to $862.00 in a research note issued on Tuesday.

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

The Conference Forum today announced the launch of the 9th annual Patients as Partners® Europe event, taking place on May 20-21, 2025 at Royal National Hotel in London, UK. The meeting offers an ...

Hello, and welcome, everyone, to the Cencora Q1 fiscal year 2025 earnings call. My name is Becky, and I'll be your operator today. (Operator Instructions) I will now hand over to your host, Head of ...

Strong private equity investment and strategic M&A in 2024, and a shift toward clinical-stage companies and asset-driven ...